Darunavir/Ritonavir Pharmacokinetics Following Coadministration With Clarithromycin in Healthy Volunteers

@article{Sekar2008DarunavirRitonavirPF,
  title={Darunavir/Ritonavir Pharmacokinetics Following Coadministration With Clarithromycin in Healthy Volunteers},
  author={V. Sekar and S. Spinosa-Guzman and E. Paepe and M. Pauw and T. Vangeneugden and E. Lefebvre and Richar M. W. Hoetelmans},
  journal={The Journal of Clinical Pharmacology},
  year={2008},
  volume={48}
}
This study investigated the steady‐state pharmacokinetic interaction between the HIV protease inhibitor, darunavir (TMC114), administered with low‐dose ritonavir (darunavir/ritonavir), and clarithromycin in HIV‐negative healthy volunteers. In a 3‐way crossover study, 18 individuals received darunavir/ritonavir 400/100 mg bid, clarithromycin 500 mg bid, and darunavir/ritonavir 400/100 mg bid plus clarithromycin 500 mg bid in 3 separate sessions for 7 days, with a washout period of at least 7… Expand
View on Wiley
ncbi.nlm.nih.gov
19 Citations
Background Citations
3
Methods Citations
1
Results Citations
1

19 Citations

Citation Type

Citation Type

The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants
  • 51
Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
  • 11
  • PDF
Ritonavir-boosted darunavir: a powerful option for treatment-experienced HIV-1-infected patients
Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
  • PDF
Pharmacotherapy Update: Treatment of HIV Infection with Darunavir
  • PDF
Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.
  • 10
Darunavir: an effective protease inhibitor for HIV-infected patients
  • 5
Darunavir: a review of its use in the management of HIV infection in adults.
  • 97
Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
  • 20
  • PDF
Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.
  • 76
...
1
2
...

References

SHOWING 1-10 OF 21 REFERENCES
Pharmacokinetic Interaction between Amprenavir and Clarithromycin in Healthy Male Volunteers
  • 35
  • PDF
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
  • 470
  • PDF
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1
  • 174
Clinical Pharmacokinetics of Clarithromycin
  • 166
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients
  • 108
Pharmacokinetic interaction between ritonavir and clarithromycin *
  • 72
The management of HIV-1 protease inhibitor pharmacokinetic interactions.
  • 50
  • PDF
Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.
  • 74
The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.
  • 53
Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro
  • 294
  • PDF
...
1
2
3
...